NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

Company Overview - NeuroSense Therapeutics Ltd. is a late-clinical stage biotechnology company focused on developing treatments for severe neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease, which represent significant unmet medical needs with limited therapeutic options available [5] Financing Details - NeuroSense has entered into a definitive agreement for a $500,000 private placement of ordinary shares, issuing 333,334 shares at a purchase price of $1.50 per share, which is a 40% premium to the closing price on September 3, 2025 [2][3] - The private placement is expected to close on September 8, 2025, subject to customary conditions, and the proceeds will be used for general corporate purposes and working capital [2] Management Commentary - The CEO of NeuroSense stated that this investment serves as a short-term bridge to advance the company's activities and prepare for the next stage of growth, emphasizing that this is the third financing with private investors at a premium to market [3]